Natera, Inc. (NASDAQ:NTRA) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC grew its holdings in Natera, Inc. (NASDAQ:NTRAFree Report) by 49.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 641 shares of the medical research company’s stock after acquiring an additional 211 shares during the quarter. GAMMA Investing LLC’s holdings in Natera were worth $101,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Chartwell Investment Partners LLC boosted its holdings in Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after acquiring an additional 11,362 shares in the last quarter. Cerity Partners LLC boosted its holdings in Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock worth $10,936,000 after acquiring an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Natera in the third quarter worth about $385,000. Jag Capital Management LLC raised its stake in shares of Natera by 8.8% in the third quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company’s stock worth $22,291,000 after purchasing an additional 14,159 shares during the last quarter. Finally, First Turn Management LLC purchased a new position in shares of Natera in the third quarter worth about $19,760,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Trading Down 0.9 %

Shares of NTRA stock opened at $175.00 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a market cap of $23.10 billion, a price-to-earnings ratio of -99.43 and a beta of 1.65. The stock has a 50 day simple moving average of $159.12 and a 200-day simple moving average of $131.68. Natera, Inc. has a 1-year low of $59.80 and a 1-year high of $177.00.

Natera (NASDAQ:NTRAGet Free Report) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) EPS. On average, equities research analysts expect that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 1,196 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $118.21, for a total transaction of $141,379.16. Following the completion of the sale, the insider now directly owns 110,695 shares in the company, valued at approximately $13,085,255.95. The trade was a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 496 shares of the business’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $119.09, for a total value of $59,068.64. Following the sale, the chief financial officer now owns 74,314 shares of the company’s stock, valued at $8,850,054.26. The trade was a 0.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 127,932 shares of company stock valued at $20,635,430 in the last three months. 7.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. TD Cowen raised their price objective on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Canaccord Genuity Group raised their price objective on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. raised their price objective on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, Robert W. Baird raised their price objective on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $158.00.

Get Our Latest Analysis on NTRA

About Natera

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Articles

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.